P–339 Fertility treatment and live birth are still possible following the unexpected diagnosis of endometrial carcinoma/complex hyperplasia - provided that there is careful multidisciplinary team involvement

2021 ◽  
Vol 36 (Supplement_1) ◽  
Author(s):  
D Roche ◽  
F Martyn ◽  
M Wingfield

Abstract Study question Is it safe for young women to delay hysterectomy for endometrial carcinoma or complex hyperplasia, have fertility treatment and carry a pregnancy to term? Summary answer Fertility treatment and livebirth are possible after a diagnosis of endometrial carcinoma or complex hyperplasia but close co-operation between fertility and gynae-oncology services is key. What is known already While predominantly a disease of postmenopausal women, 7% of cases of endometrial adenocarcinoma or complex hyperplasia occur in women under 40 years. The standard surgical treatment is hysterectomy, which is curative in the majority of cases. In younger women wishing to preserve fertility, conservative treatment may be considered. The fertility outcomes in this population are not well reported, possibly because fertility preservation is not always discussed or considered when faced with the devastating diagnosis of cancer or pre-cancer in the younger woman or because of concerns regarding the impact of pregnancy or ovarian stimulation on a predominantly oestrogen sensitive tumour. Study design, size, duration This case series retrospectively evaluated the outcomes of 6 women with endometrial adenocarcinoma or complex hyperplasia who attended Merrion Fertility Clinic, Dublin from 2013 to 2020 and who were managed conservatively. These women initially presented with a history of infertility for which they underwent routine ultrasonography, which then led to hysteroscopy and endometrial biopsy. The histopathology of all 6 women showed an incidental finding of endometrial adenocarcinoma or complex hyperplasia. Participants/materials, setting, methods Patient files and a fertility clinic online database were reviewed to identify those with a diagnosis of endometrial carcinoma or complex hyperplasia. Their treatment course and reproductive outcomes were followed up, as was there eventual definitive surgical treatment. Main results and the role of chance Six women attending our service over a 7 year period were found to have endometrial adenocarcinoma or hyperplasia. They ranged in age from 34 to 46(mean 39). All were nulliparous. Four of the women had adenocarcinoma and 2 had complex hyperplasia. One woman, aged 41, with grade II endometrial adencocarcinoma was deemed unsuitable for conservative management by the gynaecological oncology team. She underwent urgent total abdominal hysterectomy and is well. The remaining 5 women proceeded with conservative management with oral or local progesterone therapy for 6 to 12 months. This resulted in an inactive endometrium on follow-up endometrial biopsy. Once disease regression was achieved, assisted reproduction in the form of in-vitro fertilization (IVF) was advised to ensure minimal time to pregnancy. Two of the women conceived using own egg IVF and two with donor eggs. All were successful in achieving at least one live birth. One had twins and one had 2 singletons, from a fresh and a frozen embryo transfer. The 6th woman has embryos frozen but has not yet had embryo transfer. Two of the 6 women ultimately had a hysterectomy, while 4 continue to be followed up with 6 monthly endometrial biopsies and progesterone therapy. Limitations, reasons for caution This study is limited by the small sample size. However, this paper reports on a niche subset of the population and finding larger sample sizes would be difficult to obtain. Wider implications of the findings: This case series illustrates the favourable outcome of pregnancy with IVF after either systemic or local progesterone therapy in early stage endometrial adenocarcinoma or complex hyperplasia. Early involvement of a fertility specialist may prove highly valuable in cases of fertility sparing treatment to increase each patient’s potential for pregnancy. Trial registration number Not applicable

2020 ◽  
Vol 35 (3) ◽  
pp. 595-604 ◽  
Author(s):  
J Vissers ◽  
T C Sluckin ◽  
C C Repelaer van Driel-Delprat ◽  
R Schats ◽  
C J M Groot ◽  
...  

Abstract STUDY QUESTION Does a previous Caesarean section affect reproductive outcomes, including live birth, in women after IVF or ICSI? SUMMARY ANSWER A previous Caesarean section impairs live birth rates after IVF or ICSI compared to a previous vaginal delivery. WHAT IS KNOWN ALREADY Rates of Caesarean sections are rising worldwide. Late sequelae of a Caesarean section related to a niche (Caesarean scar defect) include gynaecological symptoms and obstetric complications. A systematic review reported a lower pregnancy rate after a previous Caesarean section (RR 0.91 CI 0.87–0.95) compared to a previous vaginal delivery. So far, studies have been unable to causally differentiate between problems with fertilisation, and the transportation or implantation of an embryo. Studying an IVF population allows us to identify the effect of a previous Caesarean section on the implantation of embryos in relation to a previous vaginal delivery. STUDY DESIGN, SIZE, DURATION We retrospectively studied the live birth rate in women who had an IVF or ICSI treatment at the IVF Centre, Amsterdam UMC, location VUmc, Amsterdam, the Netherlands, between 2006 and 2016 with one previous delivery. In total, 1317 women were included, of whom 334 had a previous caesarean section and 983 had previously delivered vaginally. PARTICIPANTS/MATERIALS, SETTING, METHODS All secondary infertile women, with only one previous delivery either by caesarean section or vaginal delivery, were included. If applicable, only the first fresh embryo transfer was included in the analyses. Patients who did not intend to undergo embryo transfer were excluded. The primary outcome was live birth. Multivariate logistic regression analyses were used with adjustment for possible confounders ((i) age; (ii) pre-pregnancy BMI; (iii) pre-pregnancy smoking; (iv) previous fertility treatment; (v) indication for current fertility treatment: (a) tubal, (b) male factor and (c) endometriosis; (vi) embryo quality; and (vii) endometrial thickness), if applicable. Analysis was by intention to treat (ITT). MAIN RESULTS AND THE ROLE OF CHANCE Baseline characteristics of both groups were comparable. Live birth rates were significantly lower in women with a previous caesarean section than in women with a previous vaginal delivery, 15.9% (51/320) versus 23.3% (219/941) (OR 0.63 95% CI 0.45–0.87) in the ITT analyses. The rates were also lower for ongoing pregnancy (20.1 versus 28.1% (OR 0.64 95% CI 0.48–0.87)), clinical pregnancy (25.7 versus 33.8% (OR 0.68 95% CI 0.52–0.90)) and biochemical test (36.2 versus 45.5% (OR 0.68 95% CI 0.53–0.88)). The per protocol analyses showed the same differences (live birth rate OR 0.66 95% CI 0.47–0.93 and clinical pregnancy rate OR 0.72 95% CI 0.54–0.96). LIMITATIONS, REASONS FOR CAUTION This study is limited by its retrospective design. Furthermore, 56 (16.3%) cases lacked data regarding delivery outcomes, but these were equally distributed between the two groups. WIDER IMPLICATIONS OF THE FINDINGS The lower clinical pregnancy rates per embryo transfer indicate that implantation is hampered after a caesarean section. Its relation with a possible niche (caesarean scar defect) in the uterine caesarean scar needs further study. Our results should be discussed with clinicians and patients who consider an elective caesarean section. STUDY FUNDING/COMPETING INTEREST(S) Not applicable. TRIAL REGISTRATION NUMBER This study has been registered in the Dutch Trial Register (Ref. No. NL7631 http://www.trialregister.nl).


2020 ◽  
Vol 7 (3) ◽  
Author(s):  
Afaneh Huda ◽  
Moustafa Ahmed SZ ◽  
Leiva Stephanie ◽  
Youssef Youssef ◽  
Abdullah Ahmed ◽  
...  

2021 ◽  
Author(s):  
Hilary Friedlander ◽  
Jennifer Blakemore ◽  
David McCulloh ◽  
M. Fino

Abstract Purpose: To evaluate pregnancy outcomes following embryo transfer in patients with endometrial carcinoma (EMCA) or endometrial hyperplasia (EH) who elected for fertility-sparing treatment (FST). Methods: This retrospective cohort study at a large urban university-affiliated fertility center included all patients who underwent embryo transfer after fertility-sparing treatment for EMCA or EH between January 2003 and December 2018. Primary outcomes included embryo transfer results and a live birth rate (defined as number of live births per number of transfers).Results: There were 14 patients, 3 with EMCA and 11 with EH, who met criteria for inclusion with a combined total of 40 embryo transfers. An analysis of observed outcomes by sub-group, compared to the expected outcomes at our center (patients without EMCA/EH matched for age, embryo transfer type and number, and utilization of PGT-A) showed that patients with EMCA/EH after FST had a significantly lower live birth rate than expected (Z = -5.04, df =39, p < 0.01). A sub-group analysis of the 14 euploid embryo transfers resulted in a live birth rate of 21.4% compared to an expected rate of 62.8% (Z = -3.32, df = 13, p < 0.001).Conclusions: Among patients with EMCA/EH who required assisted reproductive technology, live birth rates were lower than expected following embryo transfer when compared to patients without EMCA/EH at our center. Further evaluation of the impact of the diagnosis, treatment and repeated cavity instrumentation for FST is necessary to create an individualized and optimized approach for this unique patient population


2017 ◽  
Vol 35 (15_suppl) ◽  
pp. e17111-e17111 ◽  
Author(s):  
Sumita Trivedi ◽  
Felicia Williams ◽  
William L. Read

e17111 Background: Megestrol (M) is an effective palliative treatment for endometrial carcinoma but causes weight gain via activity at the corticosteroid receptor. Norethindrone (N) is a progestin without corticosteroid activity. We report 3 women with metastatic endometrial cancer responsive to M for whom a switch to N decreased side effects with continued cancer control. Methods: Case-series Results: 1. 62 year old with endometrial adenocarcinoma underwent surgery and chemoradiation. Lung metastases were discovered 31 months later and she began M with complete response at 13 months. She suffered weight gain and lymphedema. M was switched to N and continued for 4 years to date with weight loss and without progression. 2. 54 year old with endometrial adenocarcinoma underwent surgery and radiation. Lung metastases developed 30 months later. Chemotherapy produced response but was complicated by cerebrovascular accident. lung lesions developed 3 years later and slowly grew over the ensuing year. M was started and continued for 8 months. Her lung lesions responded but weight gain impacted her already reduced mobility. She was switched to N which has continued 11 months to date, with stable disease, without further weight gain. 3. 64 year old with a history of metastatic squamous cell carcinoma of the lung developed what was thought to be a second primary endometrial adenocarcinoma. She received surgery and radiation with pelvic recurrence 34 months later. M was started and continued for 17 months with response in pelvic and lung lesions, which proved to be metastatic endometrial carcinoma presenting before her primary. Weight gain resulted in wheelchair dependence. She was switched to N with continuing response over the ensuing 2 years. 28 months after starting N, imaging showed progression and she was switched back to M, her poor performance status precluding other treatments. She died 5 months later. Conclusions: In patients with metastatic endometrial cancer responding to megestrol, switching to norethindrone improved palliative benefit. Prospective clinical trials of norethindrone or similar progestins without corticosteroid activity should be considered for this population.


2021 ◽  
Vol 36 (Supplement_1) ◽  
Author(s):  
I Moreno ◽  
I Garcia-Grau ◽  
D Perez-Villaroya ◽  
M Gonzalez-Monfort ◽  
D Bau ◽  
...  

Abstract Study question Is there an association between the composition of the endometrial microbiota and the reproductive outcomes in infertile patients undergoing in vitro fertilization (IVF)? Summary answer The composition of the endometrial microbiota (EM) prior to embryo transfer is associated with the different reproductive outcomes: live birth, no pregnancy or clinical miscarriage. What is known already The investigation of bacterial communities in the female reproductive tract using molecular methods has revealed the existence of a continuum microbiota that extends from the vagina to the upper genital tract. Previous evidence suggests the existence of an association between the vaginal and endometrial microbiome composition with reproductive and obstetrical outcomes. Specifically, the presence of specific pathogens together with low abundance of Lactobacilli has been associated with poor IVF outcomes. Study design, size, duration Multicentre prospective observational clinical study analysing the EM of infertile patients undergoing IVF (with maternal age ≤40) or ovum donation (≤50 years). A total of 452 infertile patients undergoing IVF/ovum donation were assessed for eligibility in 13 reproductive clinics in Europe, America, and Asia. The duration of the study was 30 months and the recruitment period extended between August 2017 and February 2019 (ct.gov 03330444). Participants/materials, setting, methods Endometrial fluid and endometrial biopsy were collected during a hormonal replacement therapy cycle after 5 days of progesterone (P) administration prior to a frozen embryo transfer cycle. Endometrial microbiota (EM) composition was analyzed using 16S rRNA gene sequencing using compositional data to transform scale-invariant values in both sample types. The EM in fluid and biopsy was associated with live birth, biochemical pregnancy, clinical miscarriage, or no pregnancy. Main results and the role of chance Of the 452 patients assessed, 44 did not meet the selection criteria and were excluded for the study and 66 patients were lost to follow-up. Of the 342 remaining patients, 198 (57.9%) became pregnant [141 (41.2%) had a live birth, 27 (7.9%) had a biochemical pregnancy, 2 (0.6%) had an ectopic pregnancy, and 28 (8.2%) a clinical miscarriage], while 144 (42.1%) did not become pregnant. The baseline characteristics, clinical and embryological variables were homogeneous and no bias toward the clinical outcome categories was observed. Our association study showed that the composition of the EM was associated with the reproductive outcome in both endometrial fluid and biopsy. A dysbiotic endometrial microbiota profile composed of Atopobium, Bifidobacterium, Chryseobacterium, Gardnerella, Haemophilus, Klebsiella, Neisseria, Staphylococcus and Streptococcus was significantly associated with unsuccessful outcomes, especially no pregnancy and clinical miscarriage. In contrast, Lactobacillus was consistently enriched in patients with live birth outcomes. The EM in endometrial fluid did not fully reflect that in endometrial biopsy, although their association with clinical outcome was consistent. Limitations, reasons for caution The main limitation was the small number of biochemical pregnancy and clinical miscarriage analysed. During transcervical collection of endometrial samples caution was taken to avoid contamination with the cervix although cervical contamination cannot be fully discarded. Wider implications of the findings Our data indicate that EM dysbiosis is associated with poor clinical outcome in ART. Thus, the EM composition before embryo transfer could be a useful biomarker to consider offering an opportunity to further improve diagnosis and treatment strategies. Trial registration number Clinical trials.gov 03330444


Author(s):  
Ichiro Yamamoto ◽  
Toshiaki Tachibana ◽  
Hiroko Maruyama ◽  
Noriyuki Komatsu ◽  
Hiroyuki Kuramoto ◽  
...  

We have paid attention to the alteration of glycosyltransferase in carcinoma cells, because it might be related to the malignancy of the cells. In this connection, localization of β1-4 galactosyl transferase (β1-4 Gal T) in human endometrial carcinoma cells was examined immunocytochemically using two kinds of cell lines, each of which showed different degree of differentiation.An antibody was purified from the rabbit antiserum against the synthetic peptide, IFNRLVFRGMSC (W89) of human β1-4 Gal T coupled with KLH (keyhole limpet hemocyanine) by protein A column and peptide-affinity column chromatography. The anti-W89 serum reacts to the C-terminus of human β 1-4 Gal T and to both membrane-bound and soluble forms of the enzyme. Cell line of well differentiated endometrial adenocarcinoma (I) and that of poorly differentiated endometrial adenocarcinoma (50B) were cultivated respectively in MEM medium containing 15% FCS and 2 mM glutamine for 4 d at 37°C under 5% CO2. The cells were fixed in a mixture of 4% paraformaldehyde and 0.1% glutaraldehyde in 0.1 M Soerensen’s phosphate buffer (pH 7.4) at 4°C for 30 min, washed with PBS, then freezed and thawed. The indirect method of the peroxidase- labeled antibody technique was used for immunocytochemistry of both LM and TEM on the cell lines. The cells were dehydrated in ethanol and embedded in TAAB 812. Ultrathin sections were observed under a TEM, JEM-100S.


1965 ◽  
Vol 49 (3) ◽  
pp. 412-426 ◽  
Author(s):  
Per Bergsjö

ABSTRACT Various doses of progesterone in oil and of two progestational compounds (17α-hydroxy-19-nor-progesterone caproate and 17α-hydroxyprogesterone p-butoxyphenyl propionate) have been given to 15 patients with recurrent and/or metastatic endometrial adenocarcinoma and to one patient with metastatic cervical adenocarcinoma, for periods of up to 27 weeks. Regression of lung metastases was noted in 4 of 13 patients, softening of pelvic tumour in 2 of 4, and histological alterations of tumour tissue in 4 of 5 patients. In the patient with metastases from a cervical adenocarcinoma, the disease progressed during the treatment. The significance of the observations is discussed.


2020 ◽  
Author(s):  
Raluca Trifanescu ◽  
Dan Alexandru Niculescu ◽  
Alexandru Cristescu ◽  
Smarandoiu Georgiana Alexandra ◽  
Ramona Dobre ◽  
...  

2020 ◽  
Vol 64 (2) ◽  
Author(s):  
Humain Baharvahdat ◽  
Babak Ganjifar ◽  
Hamid Etemadrezaie ◽  
Ali Gorji

Sign in / Sign up

Export Citation Format

Share Document